June 28, 2026
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
B Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious disease areas In April, Novavax signed a new MTA…
